LEADER 04321nam 22007335 450 001 9910300353103321 005 20200701085358.0 010 $a3-642-54562-9 024 7 $a10.1007/978-3-642-54562-7 035 $a(CKB)3710000000129308 035 $a(EBL)1783275 035 $a(OCoLC)890981450 035 $a(SSID)ssj0001277452 035 $a(PQKBManifestationID)11951335 035 $a(PQKBTitleCode)TC0001277452 035 $a(PQKBWorkID)11278951 035 $a(PQKB)10292441 035 $a(MiAaPQ)EBC1783275 035 $a(DE-He213)978-3-642-54562-7 035 $a(PPN)179763121 035 $a(EXLCZ)993710000000129308 100 $a20140614d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPsychopharmacology and Pregnancy $eTreatment Efficacy, Risks, and Guidelines /$fedited by Megan Galbally, Martien Snellen, Andrew Lewis 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (231 p.) 300 $aDescription based upon print version of record. 311 $a1-322-13904-0 311 $a3-642-54561-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aIntroduction to Perinatal Psychiatry -- The Process of Obtaining Informed Consent: Including Medico-legal implications -- Methodology: How to Interpret the Literature and Level of Evidence -- Physiological Changes in Pregnancy, the Biology of Exposure and Psychopharmacology -- Outcomes for Mother and Child as a Result of Untreated Mental Illness -- Major Depressive Disorders: Anti-depressants -- Anxiety Disorders: Anxiolytics and Hypnotics -- Bipolar Affective Disorder: Mood Stabilisers -- Schizophrenia: Anti-Psychotics -- Other Disorders: Eating Disorders, Borderline Personality Disorder -- Substance Abuse Disorders -- Complementary and alternative Medicines -- ECT -- Conclusion. 330 $aThis book examines the role of psychopharmacological treatment in a range of disorders that may be encountered during pregnancy, including major depressive disorders, anxiety disorders, bipolar affective disorder, schizophrenia, eating disorders, and substance abuse. The natural history of each condition pre- and post-partum is analyzed, and the evidence for the efficacy of drug treatments, evaluated. Special attention is paid to the potential dangers of different treatment options for both mother and fetus, covering risks of malformation, pregnancy and obstetric risks, neonatal risks, and possible long-term consequences. The risks of not treating a particular condition are also analyzed. On the basis of the available evidence, management guidelines are provided that additionally take into account non-pharmacological options. Closing chapters consider the value of complementary and alternative medicine and ECT and explore future research directions. 606 $aPsychopharmacology 606 $aObstetrics 606 $aPharmacotherapy 606 $aClinical psychology 606 $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010 606 $aObstetrics/Perinatology/Midwifery$3https://scigraph.springernature.com/ontologies/product-market-codes/H26014 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 606 $aClinical Psychology$3https://scigraph.springernature.com/ontologies/product-market-codes/Y12005 615 0$aPsychopharmacology. 615 0$aObstetrics. 615 0$aPharmacotherapy. 615 0$aClinical psychology. 615 14$aPsychopharmacology. 615 24$aObstetrics/Perinatology/Midwifery. 615 24$aPharmacotherapy. 615 24$aClinical Psychology. 676 $a610 676 $a615.1 676 $a615.78 676 $a616.89 702 $aGalbally$b Megan$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aSnellen$b Martien$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aLewis$b Andrew$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300353103321 996 $aPsychopharmacology and Pregnancy$91522997 997 $aUNINA